Ligand Pharmaceuticals (LGND)
NASDAQ: LGND
· Real-Time Price · USD
101.63
-0.56 (-0.55%)
At close: Jun 02, 2025, 3:59 PM
100.01
-1.59%
After-hours: Jun 02, 2025, 04:04 PM EDT
-0.55% (1D)
| Bid | 99.78 |
| Market Cap | 1.96B |
| Revenue (ttm) | 181.49M |
| Net Income (ttm) | -132.62M |
| EPS (ttm) | -7.29 |
| PE Ratio (ttm) | -13.94 |
| Forward PE | 14.6 |
| Analyst | Buy |
| Ask | 105 |
| Volume | 85,737 |
| Avg. Volume (20D) | 122,204 |
| Open | 102.53 |
| Previous Close | 102.19 |
| Day's Range | 100.67 - 102.83 |
| 52-Week Range | 77.43 - 129.90 |
| Beta | 0.76 |
About LGND
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol LGND
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for LGND stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
+0.57%
Ligand Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
6 months ago
+11.12%
Ligand Pharmaceuticals shares are trading higher after the company reported worse-than-expected Q3 financial results and raised its FY24 guidance.
3 weeks ago · seekingalpha.com
Ligand Pharmaceuticals Incorporated (LGND) Q1 2025 Earnings Call TranscriptLigand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Melanie Herman – Executive Director-Investor Relations Todd Davis – Chie...